Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial in patients previously untreated for metastatic colorectal cancer (mCRC), and changes during treatment in plasma cytokines and angiogenic factors (CAFs) as potential markers o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2010-01, Vol.28 (3), p.453-459
Hauptverfasser:	KOPETZ, Scott, HOFF, Paulo M, LIEU, Christopher, SHAOYU YAN, TRAN, Hai T, ELLIS, Lee M, ABBRUZZESE, James L, HEYMACH, John V, MORRIS, Jeffrey S, WOLFF, Robert A, ENG, Cathy, GLOVER, Katrina Y, ADININ, Rosie, OVERMAN, Michael J, VALERO, Vincete, SIJIN WEN
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Angiogenesis Inducing Agents - blood Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Biomarkers, Tumor - blood Camptothecin - administration & dosage Camptothecin - analogs & derivatives Camptothecin - therapeutic use Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Colorectal Neoplasms - secondary Cytokines - blood Drug Resistance, Neoplasm Female Fluorouracil - therapeutic use Gastroenterology. Liver. Pancreas. Abdomen Humans Leucovorin - therapeutic use Male Medical sciences Middle Aged Original Reports Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!